AVIR Q4 2025 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$104,000

Operating Income

-$55M

Net Income

-$45M

EPS (Diluted)

$-0.57

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$315M

Total Liabilities

$40M

Stockholders' Equity

$275M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$104,000	-$104,000	+0.0%
Operating Income	-$55M	-$39M	-40.8%
Net Income	-$45M	-$34M	-33.8%